Company Profile
Zura Bio Stock Price, News & Catalysts
- Ticker:
- ZURA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.68 USD (+1.97%)
Close
Last updated: August 17, 2026
389M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ZURA closed up 1.97% at $5.68. No new same-company headline was identified in the current news window.
Company overview
Autoimmune and Inflammatory Diseases
Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules.
Tibulizumab
Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell biology involved in chronic immune-mediated disease.
TibuSHIELD
The Phase 2 TibuSHIELD study evaluates tibulizumab in adults with hidradenitis suppurativa, an inflammatory skin disease driven in part by IL-17 signaling.
TibuSURE
The Phase 2 TibuSURE study evaluates tibulizumab in adults with systemic sclerosis, where simultaneous IL-17 and BAFF inhibition may address inflammation, autoantibodies, and fibrosis.
NEXUS-PMR
Zura selected polymyalgia rheumatica as a third indication for tibulizumab. The planned Phase 2 NEXUS-PMR study extends the program into an inflammatory disorder commonly treated with long-term glucocorticoids.
Future catalysts
- Topline data from the Phase 2 TibuSHIELD study in the fourth quarter of 2026.
- Initiation of the Phase 2 NEXUS-PMR study by the end of 2026.
- Topline data from the Phase 2 TibuSURE study in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Zura Bio (ZURA)?
Zura Bio (ZURA) most recently closed at 5.68 USD, a +1.97% move versus the previous session.
What is the market cap of Zura Bio (ZURA)?
Zura Bio currently has a market capitalization of 389M USD on BioPharmSignal.
What does Zura Bio do?
Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell biology involved in...
On which exchange is ZURA stock listed?
Zura Bio (ZURA) is associated with NASDAQ, United States, Biopharma.
What is IL-17?
Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF.
Which conditions is Zura Bio targeting with IL-17?
Zura Bio is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Zura Bio describe recent progress with IL-17?
Topline data from the Phase 2 TibuSHIELD study in the fourth quarter of 2026. Initiation of the Phase 2 NEXUS-PMR study by the end of 2026. Topline data from the Phase 2 TibuSURE study in the first half of 2027.
What is NEXUS-PMR?
NEXUS-PMR Zura selected polymyalgia rheumatica as a third indication for tibulizumab.